The MycetOS (Mycetoma Open Source) project was launched today by the University of Sydney, Erasmus MC, and the Drugs for Neglected Diseases initiative (DNDi) to use an Open Pharma approach to discover compounds that could lead to new treatments for patients suffering from fungal mycetoma (eumycetoma), a devastating disease for which current treatments are ineffective, expensive, and toxic.
Drugs for Neglected Diseases initiative (DNDi)
See the following -
Africa: Partners Commit To Bolster Open Source Research
Press Release |
Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), Royal Society of Chemistry (RSC) |
November 27, 2013
The Royal Society of Chemistry (RSC), UK, Drugs for Neglected Diseases initiative (DNDi) and MMV have signed a memorandum of understanding (MoU) to collaborate in an effort to build a global community of researchers contributing to open source drug discovery for diseases of poverty. Read More »
- Login to post comments
Funding Crunch Hits Neglected Diseases Plan
Staff Writer | SciDev.Net | April 29, 2014
The Open Source Drug Discovery (OSDD) programme — a global collaborative initiative supported by the Indian government to find affordable treatment for neglected tropical diseases — has suffered a temporary setback due to a funds crunch caused by tardy submission of funding estimates. Read More »
- Login to post comments
Less Neglect, More Openness: Two ‘Grand Experiments’ In Health Innovation
Bernard Pécoul | PLOS.org | November 28, 2013
Commemorating the 10th Anniversaries of PLOS and the Drugs for Neglected Diseases initiative (DNDi), Bernard Pécoul, Executive Director of DNDi, discusses the innovative journeys of the organisations. Read More »
- Login to post comments
Major Patent Pool Opens Up Research On Neglected Disease
Yojana Sharma | SciDev.Net | October 31, 2011
Research on drug development for neglected tropical diseases (NTDs), tuberculosis and malaria will receive a boost from a major initiative launched by the World Intellectual Property Organization (WIPO) last week (26 October). Read More »
- Login to post comments
Medicines for Malaria Venture Releases Report on how R&D Partnerships Serving Neglected Communities have Developed Dozens of Life-Saving Innovations Since 2010
Press Release |
Medicines for Malaria Venture |
January 28, 2021
The public-private initiatives that contributed to COVID-19 vaccine and drug development have showcased a model for accelerating biomedical innovation. This is another powerful example of how public-private partnerships have established themselves as powerhouses for fighting global health threats. According to a new report launched today from a group of 12 product development partnerships (PDPs), over the last decade, such alliances have brought to market 66 new drugs, vaccines, diagnostics and other technologies for a number of diseases—including tuberculosis, malaria, HIV, meningitis and sleeping sickness. These innovations have reached and benefitted more than 2.4 billion people in low-income countries.
- Login to post comments
Mycetoma: The Untold Global Health Story of 2015
Brian W. Simpson | Global Health NOW | December 7, 2015
“It is unjust that people don’t care about this disease.” Writer Amy Maxmen’s words keep surfacing in my thoughts. She said this after her trip to Sudan to report on mycetoma, a flesh-eating, bone-destroying disease that spreads misery across 23 countries from Mexico to India. Although it’s exacted a horrific toll on human lives for centuries, very little is known about its prevalence or etiology. Bacterial or fungal in origin, the disease starts with a skin infection that over time grotesquely swells feet and other appendages. It erupts in painful lesions on the skin even as it destroys the bones within. Often the only treatment is amputation. Sometimes the disease proves fatal...
- Login to post comments
New Open Source Drug Discovery Project Aims to Develop Mycetoma Treatment
Press Release |
ErasmusMC , University of Sydney , DNDi |
February 6, 2018
- Login to post comments
Open Access Initiative Reveals Drug Hits For Deadly Neglected Tropical Diseases
Press Release |
Drugs for Neglected Diseases initiative (DNDi), Medicines for Malaria Venture (MMV) |
November 13, 2012
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through DNDi’s screening of MMV’s open access Malaria Box. Read More »
- Login to post comments
Recent Research Highlights Potential Of Open Access In Drug Discovery
Rachel Marusak Hermann | Intellectual Property Watch | November 14, 2012
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announced the identification of three potential drug classes for the treatment of neglected tropical diseases through the availability of hundreds of compounds in the public domain. Read More »
- Login to post comments
The Opposite of Martin Shkreli: Drug Development Without Profit
Amy Maxmen | Global Health Now | December 14, 2015
From inside the van, Nathalie Strub Wourgaft watches the scene unfold in silence. She looks tired, and a little tense. Wourgaft is the medical director of a Geneva-based organization devoted to developing treatments for syndromes that afflict the poor, called the Drugs for Neglected Diseases initiative (DNDi), and she is in Sudan for just 3 days to scope out the setting for a clinical trial that will be the first of its kind. By May, Wourgaft and a Sudanese surgeon, Ahmed Fahal, hope to test a new drug for a potentially lethal, flesh-eating fungal infection called mycetoma...
- Login to post comments
Copyright ©2011-2020 Open Health Marketplace, LLC. All Rights Reserved.